文献速递银屑病与炎症性皮肤病

阿普司特治疗中重度生殖器银屑病:32周DISCREET 3期研究结果

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-12-10

DISCREET是一项3期随机双盲试验,评估阿普司特30mg每日两次治疗中重度生殖器银屑病。289例患者随机分组,16周安慰剂对照后进入16周扩展期。32周时,安慰剂/阿普司特组51.8%和持续阿普司特组40.3%达生殖器PGA应答,安全性与既往一致。

要点

  • 阿普司特30mg每日两次治疗中重度生殖器银屑病在32周内显示持续疗效。
  • 第16周起始或随机起始阿普司特的患者在32周时疗效相似。
  • 常见不良事件为腹泻、恶心和头痛,未见新的安全性信号。

核心结论

  • 阿普司特是治疗中重度生殖器银屑病的有效口服系统疗法,在DISCREET研究中显示一致的临床疗效、症状减轻和生活质量获益。

研究设计与样本

  • DISCREET为3期多中心随机双盲试验,比较阿普司特30mg每日两次与安慰剂,16周安慰剂对照期(1:1随机)后进入16周阿普司特扩展期。
  • 纳入中重度生殖器银屑病患者,定义为生殖器静态医生总体评估(genital PGA)评分≥3,且局部治疗控制不佳或不耐受。
  • 共289例患者随机,229例继续进入扩展期(第16-32周):安慰剂/阿普司特组110例,阿普司特/阿普司特组119例。

主要发现

  • 第32周时,安慰剂/阿普司特组51.8%(95%CI:42.6,60.9)和持续阿普司特组40.3%(95%CI:32.0,49.3)的患者达到改良生殖器PGA应答(评分0/1且较基线降低≥2分)。
  • 第32周时,第16周起始阿普司特或随机起始阿普司特的患者在皮肤、生殖器体征和症状及生活质量方面观察到相似改善。
  • 全部阿普司特暴露期间常见治疗中出现的不良事件为腹泻(25.4%)、恶心(19.4%)和头痛(17.9%)。

关键数值与推荐

  • 生殖器PGA应答定义为评分0/1且较基线降低≥2分。
  • 中重度生殖器银屑病定义为改良生殖器PGA评分≥3。

临床怎么用

  • 对于局部治疗控制不佳或不耐受的中重度生殖器银屑病患者,阿普司特30mg每日两次可作为口服系统治疗选择。
  • 治疗期间需关注腹泻、恶心和头痛等常见不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genital psoriasis is highly prevalent among patients with psoriasis, is often stigmatized, causes pain and discomfort and negatively impacts quality of life. Apremilast is an oral phosphodiesterase 4 inhibitor approved for treating psoriasis and has demonstrated safety and efficacy in treating genital psoriasis, as seen in the primary 16-week DISCREET results. OBJECTIVES: To assess the efficacy and safety of apremilast 30 mg twice daily in patients with moderate to severe genital psoriasis over the 32-week study duration. METHODS: DISCREET was a phase 3, multicentre, randomized, double-blind trial that evaluated apremilast 30 mg twice daily versus placebo in a 16-week placebo-controlled phase (randomization 1:1) followed by a 16-week apremilast extension phase. Patients had moderate to severe genital psoriasis, defined as a modified static Physician's Global Assessment of Genitalia (genital PGA) score of ≥3. They also either had disease inadequately controlled by or were intolerant to topical therapy. We report the results through Week 32. RESULTS: Of 289 patients randomized, 229 continued to the apremilast extension phase (Weeks 16-32): 110 in the placebo/apremilast group and 119 in the apremilast/apremilast group. At 32 weeks, 51.8% (95% CI: 42.6, 60.9) of patients in the placebo/apremilast group and 40.3% (95% CI: 32.0, 49.3) of patients in the apremilast/apremilast group had achieved a modified genital PGA response (score of 0/1 with ≥2-point reduction from baseline). At Week 32, similar improvements in skin, genital signs and symptoms and quality of life were observed in patients who started apremilast at Week 16 or at randomization. Frequently reported treatment-emergent adverse events during all-apremilast exposure were diarrhoea (25.4%), nausea (19.4%) and headache (17.9%). CONCLUSIONS: Apremilast is an effective oral systemic therapy in patients with moderate to severe genital psoriasis and has shown consistent clinical efficacy, lessening of symptoms and quality-of-life benefit in DISCREET. CLINICAL TRIAL ID: NCT03777436. Patients with psoriasis often have symptoms in the genital area. Genital psoriasis can cause uncomfortable symptoms such as itching, burning, flaking, and pain, as well as embarrassment and negative effects on sexual and mental health. Few clinical studies have focused on treatments specifically for genital psoriasis. Steroid creams are commonly prescribed, however some patients dislike this treatment due to side effects, inconvenience, messiness, and lack of effectiveness. In the multinational DISCREET study, we examined how effective and safe ‘apremilast’ (an oral medication) was in treating moderate to severe genital psoriasis. We previously reported that apremilast was safe and effective over 16 weeks compared to ‘placebo’ (a dummy drug containing no active ingredients). Here we report the long‐term results over 32 weeks. In total, 289 patients received either apremilast or placebo for 16 weeks, after which all patients received apremilast until week 32. At 32 weeks, nearly half (46%) of all patients achieved clear or almost clear genital skin; patients who received apremilast throughout the entire 32‐week study and patients who switched from placebo to apremilast at 16 weeks experienced similar effectiveness. Patients also had improvements in genital itch and other symptoms, as well as in general and sexual well‐being. Both women and men benefited from apremilast, with the benefit more pronounced in women. No new safety concerns were identified compared to previous studies. In conclusion, these findings indicate that apremilast is an effective and safe oral medication for patients with moderate to severe genital psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Merola JF, Guenther L, Lynde C, et al. Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis. J Eur Acad Dermatol Venereol. 2025. PMID: 41369155. doi:10.1111/jdv.70110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。